Direct thrombin inhibition: A novel approach to stroke prevention in patients with atrial fibrillation

Stroke

Volumn 35, Issue 6, 2004, Pages 1519-1522

  Elkind, Mitchell S V ^a,b,d   Sacco, Ralph L ^a,b,c  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b Taub Institute for Research on Alzheimer's Disease and the Aging Brain and the Gertrude H Sergievsky Center   (United States)

^c Neurological Institute ^*  (United States)

^d NEUROLOGICAL INSTITUTE   (United States)

Author keywords

Atrial fibrillation; Cerebral embolism; Direct thrombin inhibitor; Stroke prevention; Ximelagatran

Indexed keywords

ACETYLSALICYLIC ACID; ARGATROBAN; HIRUDIN; MELAGATRAN; PLACEBO; THROMBIN; THROMBIN INHIBITOR; WARFARIN; XIMELAGATRAN;

CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG CLEARANCE; DRUG MECHANISM; EMBOLISM; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PHARMACODYNAMICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; STROKE; TRANSIENT ISCHEMIC ATTACK;

AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; AZETIDINES; BENZYLAMINES; CEREBROVASCULAR ACCIDENT; HUMANS; RANDOMIZED CONTROLLED TRIALS; THROMBIN; WARFARIN;

EID: 2542601675     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.0000128883.89984.52     Document Type: Review

References (13)

1. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22:983-988.
2. Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: the Copenhagen AFASAK Study. Lancet. 1989;1:175-179.
3. Boston Area Anticoagulation Trial in Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with non-rheumatic atrial fibrillation. N Engl J Med. 1990;323:1505-1511.
4. Stroke Prevention in Atrial Fibrillation Investigators. Warfarin versus aspirin for the prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II study. Lancet. 1994;343: 687-691.
5. Albers GW, Dalen JE, Laupacis A. Manning WJ, Petersen P, Singer DE. Antithrombotic therapy in atrial fibrillation. Chest. 2001;119:194S-206S.
6. Van Walraven C, Hart RG, Singer DE, Laupacis A, Connolly S, Petersen P, Koudstaal PJ, Chang Y, Hellemons B, Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation. An individual patient meta-analysis. JAMA 2002;288:2441-2448.
7. EAFT (European Atrial Fibrillation Trial) Study Group. Secondary prevention in nonrheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet. 1993;342:1255-1262.
8. Goldstein LB, Adams R, Becker K, Furberg CD, Gorelick PB, Hademenos G, Hill M, Howard G, Howard VJ, Jacobs B, Levine SR, Mosca L, Sacco RL, Sherman DG, Wolf PA, del Zoppo GJ. Primary prevention of ischemic stroke: a statement for healthcare professionals from the stroke council of the American Heart Association. Circulation. 2001;103:163-182.
9. Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter: stroke prevention in patients with nonvalvular atrial fibrillation. Neurology. 1998;51:671-673.
10. Bo S, Ciccone G, Scaglione L, Taliano C, Piobbici M, Merletti F, Pagano G. Warfarin for non-valvar atrial fibrillation: still underused in the 21st century? Heart. 2003;89:553-554.
11. McCrory DC, Mathcar DB, Samsa G. Physician attitudes about anticoagulation for nonvalvular atrial fibrillation in the elderly. Arch Intern Med. 1995;155:277-281.
12. Bates SM, Weitz JI. Emerging anticoagulant drugs. Arterioscler Thromb Vasc Biol. 2003;23:1491-1500.
13. Halperin JL, for the SPORTIF Investigators. Presented at: American Heart Association Scientific Sessions; November 9-12, 2003; Orlando, Fla.